BCA’s capex set to IDR 8.7 trillion, most goes to technology upgrade
08 Aug 2023 14:19
PT Bank Central Asia Tbk (BBCA) allocates capital expenditure (capex) budget of IDR 8.7 trillion this year.
Expanding, HEAL to allocate capex of IDR 1.2 trillion
07 Aug 2023 14:04
PT Medikaloka Hermina Tbk (HEAL), the owner of Hermina Hospital network, is allocating capital expenditure (capex) of IDR 1.2 trillion until the end of 2023.
Acquiring materials, PPRI aims for IDR 38.5 billion in IPO
04 Aug 2023 12:19
PT Paperocks Indonesia Tbk (PPRI) eyes extra working capital worth IDR 38.5 billion via initial public offering (IPO) of 275 million shares for IDR 140 each.
WIFI to set up rights issue of 4.96 billion shares
01 Aug 2023 15:53
PT Solusi Sinergi Digital Tbk (WIFI) plans to issue 4.96 billion shares in rights issue valued at IDR 100 per share.
PAM still has IDR 45.58 billion capex from IPO
14 Jul 2023 14:27
PT PAM Mineral Tbk (NICL) still has IDR 45.58 billion left from the initial public offering (IPO) until the first half of 2023. The unrealized funds are much more than the capital expenditure allocation.
MIDI prepares IDR 373.55 billion capex
13 Jul 2023 11:08
PT Midi Utama Indonesia Tbk (MIDI), the manager of Alfamidi's modern retail, is preparing IDR 373.55 billion for capital expenditure.
Nusantara Investama now controls BUVA
04 Jul 2023 10:36
The shareholders PT Bukit Uluwatu Villa Tbk (BUVA) agree upon the debt restructuring through the debt conversion mechanism, turning it into equity via a private placement.
Bank IBK seeks IDR 1.38 trillion in rights issue
03 Jul 2023 18:32
PT Bank IBK Indonesia Tbk (AGRS) aims to raise an extra capital worth IDR 1.38 trillion via its fifth rights issue, offering 13.81 billion shares.
Shareholders approve PTDU's rights issue plan
20 Jun 2023 06:18
The shareholders agreed upon PT Djasa Ubersakti Tbk's (PTDU) plan to raise fresh funds via a rights issue of 1.5 billion shares.
COVID-19 crisis subsides, Diagnos Lab eyes 2023 realistically
19 Jun 2023 11:49
PT Diagnos Laboratorium Utama Tbk (DGNS), a clinical laboratory service provider under Bundamedik Group, is anticipating the decline in its revenue and profit post COVID-19 crisis.
